Trials / Completed
CompletedNCT01930162
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
A Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Infusing HSC835 in Patients With Hematological Malignancies Undergoing UCB Transplantation Using a Non-myeloablative Conditioning Regimen
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA) conditioning.
Conditions
- Single Umbilical Cord Blood Transplantation
- Non-myeloablative Conditioning
- Acute Lymphocytic Leukemia
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSC835 | HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC). |
Timeline
- Start date
- 2014-10-07
- Primary completion
- 2016-08-29
- Completion
- 2016-08-29
- First posted
- 2013-08-28
- Last updated
- 2021-01-05
- Results posted
- 2017-08-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01930162. Inclusion in this directory is not an endorsement.